BR112014008529A2 - il-6 humanizado e receptor de il-6 - Google Patents

il-6 humanizado e receptor de il-6

Info

Publication number
BR112014008529A2
BR112014008529A2 BR112014008529A BR112014008529A BR112014008529A2 BR 112014008529 A2 BR112014008529 A2 BR 112014008529A2 BR 112014008529 A BR112014008529 A BR 112014008529A BR 112014008529 A BR112014008529 A BR 112014008529A BR 112014008529 A2 BR112014008529 A2 BR 112014008529A2
Authority
BR
Brazil
Prior art keywords
mouse
mice
receptor
human
endogenous
Prior art date
Application number
BR112014008529A
Other languages
English (en)
Portuguese (pt)
Inventor
J Murphy Andrew
T Dore Anthony Jr
Wang Li-Hsien
Stevens Sean
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112014008529A2 publication Critical patent/BR112014008529A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014008529A 2011-10-28 2012-10-29 il-6 humanizado e receptor de il-6 BR112014008529A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552900P 2011-10-28 2011-10-28
US201161556579P 2011-11-07 2011-11-07
PCT/US2012/062379 WO2013063556A1 (en) 2011-10-28 2012-10-29 Humanized il-6 and il-6 receptor

Publications (1)

Publication Number Publication Date
BR112014008529A2 true BR112014008529A2 (pt) 2017-04-18

Family

ID=47295138

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008529A BR112014008529A2 (pt) 2011-10-28 2012-10-29 il-6 humanizado e receptor de il-6

Country Status (27)

Country Link
US (10) US8878001B2 (enExample)
EP (2) EP2663575B1 (enExample)
JP (2) JP6120451B2 (enExample)
KR (2) KR102234632B1 (enExample)
CN (2) CN104039821A (enExample)
AU (1) AU2015207889B2 (enExample)
BR (1) BR112014008529A2 (enExample)
CA (1) CA2853731C (enExample)
CY (2) CY1116614T1 (enExample)
DK (2) DK2818478T3 (enExample)
ES (2) ES2525368T3 (enExample)
HR (2) HRP20141192T1 (enExample)
HU (1) HUE033400T2 (enExample)
IL (4) IL231896B (enExample)
IN (1) IN2014CN03920A (enExample)
LT (1) LT2818478T (enExample)
MX (1) MX358390B (enExample)
MY (2) MY186903A (enExample)
PL (2) PL2818478T3 (enExample)
PT (2) PT2663575E (enExample)
RS (2) RS55949B1 (enExample)
RU (2) RU2634417C2 (enExample)
SG (3) SG10202100485XA (enExample)
SI (2) SI2818478T1 (enExample)
SM (2) SMT201700222T1 (enExample)
WO (1) WO2013063556A1 (enExample)
ZA (1) ZA201402635B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700852T3 (es) 2009-10-06 2019-02-19 Regeneron Pharma Ratones modificados genéticamente e injerto
DK3375284T3 (da) 2011-02-15 2023-06-12 Univ Yale Humaniserede M-CSF-mus og anvendelser deraf
RS55949B1 (sr) 2011-10-28 2017-09-29 Regeneron Pharmaeuticals Inc Humanizovani il-6 i il-6 receptor
US20130261016A1 (en) * 2012-03-28 2013-10-03 Meso Scale Technologies, Llc Diagnostic methods for inflammatory disorders
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
EP4193834B1 (en) 2012-09-07 2025-05-14 Yale University Methods of using genetically modified mice
WO2014042251A1 (ja) * 2012-09-13 2014-03-20 中外製薬株式会社 遺伝子ノックイン非ヒト動物
KR102402806B1 (ko) 2012-11-05 2022-05-30 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
WO2014130667A1 (en) 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
GB2513884B (en) 2013-05-08 2015-06-17 Univ Bristol Method and apparatus for producing an acoustic field
LT3175706T (lt) * 2013-09-23 2019-02-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą signalą reguliuojančio baltymo geną
RU2674910C2 (ru) * 2013-10-15 2018-12-13 Регенерон Фармасьютикалс, Инк. Животные с гуманизированным геном il-15
US20150143559A1 (en) 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
WO2015077071A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
US9612658B2 (en) 2014-01-07 2017-04-04 Ultrahaptics Ip Ltd Method and apparatus for providing tactile sensations
US9840543B2 (en) 2014-01-31 2017-12-12 Boehringer Ingelheim International Gmbh Anti-BAFF antibodies
KR102439412B1 (ko) 2014-04-08 2022-09-02 리제너론 파아마슈티컬스, 인크. 인간화된 Fc-감마 수용체를 갖는 비-인간 동물
CA3225091A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
RU2711744C1 (ru) 2014-05-19 2020-01-21 Ридженерон Фармасьютикалз, Инк. Генетически модифицированные животные, отличные от человека, экспрессирующие epo человека
EP3381279B1 (en) 2014-05-30 2021-04-14 Regeneron Pharmaceuticals, Inc. Humanized dipeptidyl peptidase iv (dpp4) animals
RS60097B1 (sr) 2014-06-19 2020-05-29 Regeneron Pharma Ne-humane životinje koje imaju humanizovani gen za programiranu ćelijsku smrt 1
GB2530036A (en) 2014-09-09 2016-03-16 Ultrahaptics Ltd Method and apparatus for modulating haptic feedback
CA2967823A1 (en) 2014-11-24 2016-06-02 Regeneron Pharmaceuticals, Inc. Non-human animals expressing humanized cd3 complex
SMT201900178T1 (it) * 2014-12-05 2019-05-10 Regeneron Pharma Animali diversi dall’uomo aventi un gruppo umanizzato del gene 47 di differenziazione
IL282649B (en) 2014-12-09 2022-07-01 Regeneron Pharma Non-human animals with a humanized gene for differentiation cluster 274
SG11201706527QA (en) 2015-02-20 2017-09-28 Ultrahaptics Ip Ltd Algorithm improvements in a haptic system
MX2017010254A (es) 2015-02-20 2018-03-07 Ultrahaptics Ip Ltd Percepciones en un sistema haptico.
RS64540B1 (sr) 2015-04-06 2023-09-29 Regeneron Pharma Imunski odgovori posredovani humanizovanim t ćelijama kod ne-humanih životinja
WO2016168212A1 (en) 2015-04-13 2016-10-20 Regeneron Pharmaceuticals, Inc. Humanized sirpa-il15 knockin mice and methods of use thereof
US10818162B2 (en) 2015-07-16 2020-10-27 Ultrahaptics Ip Ltd Calibration techniques in haptic systems
PL3376857T3 (pl) 2015-11-20 2021-09-13 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek posiadające humanizowany gen aktywacji limfocytów 3
DK3782639T3 (da) 2015-12-08 2022-08-29 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
US11189140B2 (en) 2016-01-05 2021-11-30 Ultrahaptics Ip Ltd Calibration and detection techniques in haptic systems
CN108779159B (zh) 2016-02-04 2022-12-30 瑞泽恩制药公司 具有经改造的angptl8基因的非人动物
EP3422845B1 (en) 2016-02-29 2021-06-02 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
PT3462853T (pt) 2016-06-03 2023-04-21 Regeneron Pharma Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena
US10531212B2 (en) 2016-06-17 2020-01-07 Ultrahaptics Ip Ltd. Acoustic transducers in haptic systems
US10268275B2 (en) 2016-08-03 2019-04-23 Ultrahaptics Ip Ltd Three-dimensional perceptions in haptic systems
US10755538B2 (en) 2016-08-09 2020-08-25 Ultrahaptics ilP LTD Metamaterials and acoustic lenses in haptic systems
CN107815467B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
US10943578B2 (en) 2016-12-13 2021-03-09 Ultrahaptics Ip Ltd Driving techniques for phased-array systems
US10497358B2 (en) 2016-12-23 2019-12-03 Ultrahaptics Ip Ltd Transducer driver
CN108467873B (zh) 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
WO2018177441A1 (en) * 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα
CN108588126B (zh) 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Cd47基因人源化改造动物模型的制备方法及应用
BR112020003609A2 (pt) 2017-09-29 2020-09-01 Regeneron Pharmaceuticals, Inc. sistema e método para formar uma emulsão
US11531395B2 (en) 2017-11-26 2022-12-20 Ultrahaptics Ip Ltd Haptic effects from focused acoustic fields
CN116064611A (zh) 2017-11-30 2023-05-05 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
WO2019122912A1 (en) 2017-12-22 2019-06-27 Ultrahaptics Limited Tracking in haptic systems
WO2019122916A1 (en) 2017-12-22 2019-06-27 Ultrahaptics Limited Minimizing unwanted responses in haptic systems
CN116420679B (zh) 2018-03-26 2025-10-03 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
JP7354146B2 (ja) 2018-05-02 2023-10-02 ウルトラハプティクス アイピー リミテッド 改善された音響伝達効率のための遮断板構造体
WO2020018511A1 (en) * 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
US11098951B2 (en) 2018-09-09 2021-08-24 Ultrahaptics Ip Ltd Ultrasonic-assisted liquid manipulation
US11378997B2 (en) 2018-10-12 2022-07-05 Ultrahaptics Ip Ltd Variable phase and frequency pulse-width modulation technique
WO2020125639A1 (en) * 2018-12-17 2020-06-25 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric genes
WO2020141330A2 (en) 2019-01-04 2020-07-09 Ultrahaptics Ip Ltd Mid-air haptic textures
US12373033B2 (en) 2019-01-04 2025-07-29 Ultrahaptics Ip Ltd Mid-air haptic textures
WO2020147829A1 (zh) * 2019-01-17 2020-07-23 北京百奥赛图基因生物技术有限公司 人源化转基因动物
AU2020253532B2 (en) 2019-04-04 2024-06-20 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
US11842517B2 (en) 2019-04-12 2023-12-12 Ultrahaptics Ip Ltd Using iterative 3D-model fitting for domain adaptation of a hand-pose-estimation neural network
EP3978607B1 (en) * 2019-05-27 2025-08-20 Transgenic Inc. Exon-humanized mouse
CN113874510A (zh) 2019-06-04 2021-12-31 瑞泽恩制药公司 包括具有β滑移突变的人源化TTR基因座的非人动物和使用方法
US11622547B2 (en) 2019-06-07 2023-04-11 Regeneran Pharmaceuticals, Inc. Genetically modified mouse that expresses human albumin
US11374586B2 (en) 2019-10-13 2022-06-28 Ultraleap Limited Reducing harmonic distortion by dithering
CN114631139A (zh) 2019-10-13 2022-06-14 超飞跃有限公司 利用虚拟麦克风进行动态封顶
US11169610B2 (en) 2019-11-08 2021-11-09 Ultraleap Limited Tracking techniques in haptic systems
CN111304246B (zh) * 2019-12-17 2021-05-04 百奥赛图江苏基因生物技术有限公司 一种人源化细胞因子动物模型、制备方法及应用
US11715453B2 (en) 2019-12-25 2023-08-01 Ultraleap Limited Acoustic transducer structures
EP4096396A1 (en) * 2020-01-28 2022-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
KR20230004472A (ko) 2020-04-21 2023-01-06 리제너론 파마슈티칼스 인코포레이티드 인간화 cxcl13 유전자를 갖는 비인간 동물
US11816267B2 (en) 2020-06-23 2023-11-14 Ultraleap Limited Features of airborne ultrasonic fields
US11886639B2 (en) 2020-09-17 2024-01-30 Ultraleap Limited Ultrahapticons
JP2024512702A (ja) 2021-03-31 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔｃｒβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス
US20240224964A9 (en) 2022-09-29 2024-07-11 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2025250495A1 (en) 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2202549C (en) * 1994-10-14 2003-08-05 Tara Seshadri Transgenic nonhuman animal having functionally disrupted interleukin-1.beta. converting enzyme gene
EP0791359A4 (en) 1994-10-21 2002-09-11 Chugai Pharmaceutical Co Ltd MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES
US20030082721A1 (en) * 2001-01-17 2003-05-01 Tai-Jay Chang Transgenic animals expressing androgen receptor complex-associated protein
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
PT2767161T (pt) 2004-10-19 2018-04-20 Regeneron Pharma Método para gerar um animal homozigótico para uma modificação genética
US7759541B2 (en) * 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
CN101506235B (zh) * 2006-09-01 2012-07-25 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
FR2942218A1 (fr) 2009-02-13 2010-08-20 Eurocave Sa Appareil de service au verre d'un liquide, notamment de vin
ES2700852T3 (es) 2009-10-06 2019-02-19 Regeneron Pharma Ratones modificados genéticamente e injerto
SG181690A1 (en) * 2009-12-21 2012-07-30 Regeneron Pharma Humanized fcy r mice
DK3375284T3 (da) 2011-02-15 2023-06-12 Univ Yale Humaniserede M-CSF-mus og anvendelser deraf
TW201945034A (zh) * 2011-09-30 2019-12-01 日商中外製藥股份有限公司 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子
AU2012324016C1 (en) 2011-10-28 2018-02-15 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
RS55949B1 (sr) 2011-10-28 2017-09-29 Regeneron Pharmaeuticals Inc Humanizovani il-6 i il-6 receptor
SMT202200205T1 (it) 2011-10-28 2022-07-21 Regeneron Pharma Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii

Also Published As

Publication number Publication date
CN108866101A (zh) 2018-11-23
RS53683B1 (sr) 2015-04-30
JP2014532416A (ja) 2014-12-08
JP6120451B2 (ja) 2017-04-26
US20180271071A1 (en) 2018-09-27
LT2818478T (lt) 2017-06-12
WO2013063556A8 (en) 2014-04-17
ZA201402635B (en) 2015-09-30
PL2818478T3 (pl) 2017-09-29
US9125386B2 (en) 2015-09-08
SMT201400187B (it) 2015-01-15
NZ623145A (en) 2015-09-25
NZ709432A (en) 2015-12-24
US20150013022A1 (en) 2015-01-08
IL231896A0 (en) 2014-05-28
IL243666A0 (en) 2016-03-31
IL231896B (en) 2018-02-28
US20200008407A1 (en) 2020-01-09
KR102084927B1 (ko) 2020-03-06
HRP20170656T1 (hr) 2017-06-30
US20150272092A1 (en) 2015-10-01
SI2818478T1 (sl) 2017-07-31
EP2663575A1 (en) 2013-11-20
RU2017129763A3 (enExample) 2020-12-18
AU2015207889A1 (en) 2015-08-20
US10004211B2 (en) 2018-06-26
US9622460B2 (en) 2017-04-18
SG10201600965YA (en) 2016-03-30
US8878001B2 (en) 2014-11-04
MY172726A (en) 2019-12-11
MY186903A (en) 2021-08-26
ES2624605T3 (es) 2017-07-17
RS55949B1 (sr) 2017-09-29
JP2017035115A (ja) 2017-02-16
ES2525368T3 (es) 2014-12-23
MX2014004900A (es) 2014-08-26
IN2014CN03920A (enExample) 2015-09-04
PL2663575T3 (pl) 2015-03-31
CA2853731C (en) 2021-05-18
EP2818478B1 (en) 2017-02-01
US20220053742A1 (en) 2022-02-24
KR102234632B1 (ko) 2021-04-02
CY1118952T1 (el) 2018-01-10
IL264508B (en) 2019-12-31
CN104039821A (zh) 2014-09-10
HK1205135A1 (en) 2015-12-11
IL243665A0 (en) 2016-03-31
US9078418B2 (en) 2015-07-14
RU2014121324A (ru) 2015-12-10
KR20200024949A (ko) 2020-03-09
HUE033400T2 (en) 2017-12-28
US20250287931A1 (en) 2025-09-18
SI2663575T1 (sl) 2015-01-30
US12239111B2 (en) 2025-03-04
PT2818478T (pt) 2017-05-12
PT2663575E (pt) 2014-12-05
RU2751240C2 (ru) 2021-07-12
WO2013063556A4 (en) 2013-06-20
US20130117873A1 (en) 2013-05-09
RU2634417C2 (ru) 2017-10-26
EP2663575B1 (en) 2014-10-01
MX358390B (es) 2018-08-17
RU2017129763A (ru) 2019-02-05
SMT201700222T1 (it) 2017-07-18
HRP20141192T1 (hr) 2015-02-13
US20150013023A1 (en) 2015-01-08
IL243666B (en) 2019-02-28
IL264508A (en) 2019-02-28
CA2853731A1 (en) 2013-05-02
WO2013063556A1 (en) 2013-05-02
IL243665B (en) 2018-02-28
US10433528B2 (en) 2019-10-08
CY1116614T1 (el) 2017-03-15
US20170055506A1 (en) 2017-03-02
AU2015207889B2 (en) 2017-02-23
HK1190408A1 (en) 2014-07-04
DK2663575T3 (en) 2014-12-15
US9392777B2 (en) 2016-07-19
EP2818478A1 (en) 2014-12-31
SG11201400945UA (en) 2014-04-28
DK2818478T3 (en) 2017-05-22
KR20140091024A (ko) 2014-07-18
SG10202100485XA (en) 2021-02-25
US20160278352A1 (en) 2016-09-29
US11102962B2 (en) 2021-08-31

Similar Documents

Publication Publication Date Title
BR112014008529A2 (pt) il-6 humanizado e receptor de il-6
EA201491470A1 (ru) Композиции фактора viii и способы получения и использования подобных
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
BR112013033671A2 (pt) composições de polipeptídeo de fusão fc livre de arginina e métodos de uso
BR112013027229A2 (pt) composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas
MY175708A (en) Dna antibody constructs and method of using same
BR112014029066A2 (pt) composição para a redução das sensações de trpa1 e trpv1
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
BR112016005526A2 (pt) anticorpos receptores de fator de crescimento anti-epidérmido modificado e métodos de uso dos mesmos
BR112015027528A2 (pt) polipeptídeo, combinação farmacêutica, métodos de tratamento de um distúrbio metabólico e de obesidade, uso de um polipeptídeo ou de uma combinação farmacêutica, molécula de ácido nucleico, vetor de expressão, e, célula hospedeira
BR112016001114A2 (pt) membros da família tnf direcionados modificados
BR112014017165A8 (pt) polipeptídeos de fator quimérico viii e seus usos
BR112014029252B8 (pt) Método para a construção de uma célula hospedeira fúngica recombinante, célula hospedeira fúngica recombinante, e, método de produção de um polipeptídeo de interesse
BR112015026325A2 (pt) dosagem oral de compostos glp-1
MX2013008702A (es) Composiciones que contienen anticuerpos glicosilados y sus usos.
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112015027757A2 (pt) elastômeros parcialmente fluorados e métodos para a produção e uso dos mesmos
BR112015008612A2 (pt) métodos de tratamento utilizando adenovirus
BR112018011838A2 (pt) terapia gênica para distúrbios oculares
MX391136B (es) FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
BR112012017483A2 (pt) previsão e redução de aloimunogenicidade de terapêuticos de proteína

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements